Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Invest New Drugs. 2018 Jul 28;37(1):147–158. doi: 10.1007/s10637-018-0646-1

Fig. 4. Circulating levels of CA125 and VEGF-A in a subject with ovarian cancer following treatment with U3–1565.

Fig. 4

A 76 year old female with ovarian cancer treated with U3–1565 at 24 mg/kg/week (Part 2) experienced prolonged SD, characterized by a sustained decrease in CA125 and VEGF-A levels. This subject had a high baseline VEGF-A level (18,645 pg/mL). Both CA125 (a) and VEGF-A (b) levels decreased over time upon U3–1565 treatment